MEDICOX Co., Ltd. Logo

MEDICOX Co., Ltd.

Developing new drugs and building a distribution platform for healthcare solutions.

054180 | KO

Overview

Corporate Details

ISIN(s):
KR7054180005
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 549 2~3층 (청담동, 블루펄빌딩), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MEDICOX Co., Ltd., formerly known as ChoongAng Ocean Co Ltd, has transitioned its business focus. The company's legacy operations involved the manufacture and sale of shipbuilding materials, specializing in producing blocks for vessel components like the bow, stern, propeller boss, and engine room. Following its name change, MEDICOX has pivoted towards the healthcare and pharmaceutical industry. Current strategic initiatives include new drug development and the establishment of a healthcare solutions distribution platform. The company aims to build a medical distribution network to create synergies with development and manufacturing partners in the healthcare sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 6.4 KB
2025-09-11 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.4 KB
2025-09-02 00:00
Delisting Announcement
기타시장안내 (상장적격성 실질심사 대상 결정)
Korean 4.9 KB
2025-09-02 00:00
Delisting Announcement
주권매매거래정지기간변경 (상장적격성 실질심사 대상 결정)
Korean 4.7 KB
2025-08-29 00:00
Board/Management Information
대표이사변경
Korean 9.0 KB
2025-08-29 00:00
Board/Management Information
대표집행임원변경
Korean 9.1 KB
2025-08-26 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 9.8 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.3 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-08-11 00:00
Regulatory News Service
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내)
Korean 3.2 KB
2025-08-11 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 15.1 KB
2025-08-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 92.1 KB
2025-08-11 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 63.3 KB
2025-08-06 00:00
Share Issue/Capital Change
전환가액의조정
Korean 11.0 KB
2025-07-31 00:00
Delisting Announcement
주권매매거래정지기간변경 (감자 주권 변경상장)
Korean 4.9 KB

Automate Your Workflow. Get a real-time feed of all MEDICOX Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MEDICOX Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MEDICOX Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Imunon, Inc. Logo
Developing DNA-based immunotherapies for oncology and infectious diseases.
United States of America
IMNN
IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX

Talk to a Data Expert

Have a question? We'll get back to you promptly.